FogPharma Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- FogPharma's estimated annual revenue is currently $10.7M per year.
- FogPharma received $66.0M in venture funding in May 2018.
- FogPharma's estimated revenue per employee is $155,000
- FogPharma's total funding is $112.6M.
- FogPharma has 69 Employees.
- FogPharma grew their employee count by 23% last year.
- FogPharma currently has 12 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Cell Signaling ...||$89.4M||577||N/A||N/A|
What Is FogPharma?
FogPharma is dedicated to the creation of a new class of medicines that target human disease drivers currently considered undruggable. The company's cell-penetrating miniproteins (CPMPs) combine the targeting power of protein therapeutics with the cell-penetrating ability of small molecules. This unique combination of targeting features enables CPMP's to access and engage proteins that have long been known to play a major role in causing serious human diseases, but have been frustratingly beyond the reach of therapeutic intervention. We are a vibrant and driven group of scientists and science lovers, with a strong entrepreneurial spirit, and deeply committed to our mission of adding years to life and life to years through the creation of transformative new medicines.keywords:N/A
Number of Employees
Employee Growth %
|Martin Tremblay||Executive Director, Chemistry||Email Available|
|Ivan Jewett||Principal Scientist||Email Available|
|Yaguang Si||Associate Director, Biology||Email Available|
|Howard Young||Vice President Finance||Email Available|
|Kerry Marasa||HR Business Partner|
|Ty Thomson||Senior Principal Scientist, Computational Biology||Email Available|
|James Madsen||Principal Scientist||Email Available|
|Zhang Yue-Mei||Senior Director|
|Diana Chai||Associate Director, Biology||Email Available|
|Thomas Bruton||Principal Research Associate, Chemistry||Email Available|
CAMBRIDGE — For nearly 20 years, Robert Schlager has been working on turning the old Alewife campus of renowned consulting firm Arthur ...
Howard Stern and Peter Fekkes join FogPharma as the biotech advances a beta-catenin inhibitor program for multiple cancers. (Pixabay).
“We are thrilled that FogPharma has chosen to remain at CDP and expand in Building 400-500,” said Mike Wilcox, SVP, Director of Leasing at ...
|2018-05-17||$66.0M||B||6 Dimensions Capital||Article|